P006 Hidradenitis Suppurativa: Case-Based Clinical Pearls
DESCRIPTION
Key updates in the field of hidradenitis suppurativa will be highlighted. Management strategies for both patients with milder HS and for those who are biologic candidates will be discussed. Discussion topics include how to approach layering therapy, choosing the first biologic, multi-biologic failure, and therapeutic drug monitoring. HS procedures that a dermatologist can perform in their office will be outlined and practical wound care tips will be reviewed. Management of pregnant and pediatric patients with HS will also be discussed. This symposium will provide tips to the practicing dermatologist on how to optimize their care for patients with HS that are relevant to real-life practice.
LEARNING OBJECTIVES
Utilize up-to-date evidence to optimize management of patients who have milder HS, patients who are biologic candidates, and patients who have failed multiple treatments
Implement HS procedures into your practice and improve your approach to wound care for HS
Identify strategies to manage challenging scenarios in HS management, including pregnancy and pediatrics
SCHEDULE
6:00 PM
HS in the News: Updates you don't want to miss!
Maria Aleshin, MD, FAAD
6:15 PM
My patient has mild HS: what can I offer them?
Jennifer Lin Hsiao, MD, FAAD
6:35 PM
Biologics: How to choose and When to switch
Alexandra P Charrow, MD, FAAD
6:55 PM
What to do for severe, recalcitrant HS
Jennifer Lin Hsiao, MD, FAAD
7:15 PM
HS Procedures: You Can Do It!
Christopher John Sayed, MD, FAAD
7:40 PM
Practical wound care tips for HS
Steven Daniel Daveluy, MD, FAAD
8:00 PM
HS in women and children
Katrina Lee, MD, FAAD
8:15 PM
Syndromic HS: When to Suspect and Tips to Manage
Jonathan W Rick, MD, FAAD
8:30 PM
On the Horizon: What’s Next for HS Therapies?
Natalie Fragoso, MD, FAAD
8:45 PM
Q&A
SPEAKERS
Maria Aleshin, MD, FAAD
Alexandra P Charrow, MD, FAAD
Steven Daniel Daveluy, MD, FAAD
Wayne State University
Natalie Fragoso, MD, FAAD
Jennifer Lin Hsiao, MD, FAAD
Katrina Lee, MD, FAAD
Jonathan W Rick, MD, FAAD
University of California, Davis
Christopher John Sayed, MD, FAAD
SPEAKER DISCLOSURES
Maria Aleshin, MD, FAAD
Mirador – Consultant (1099 relationship)(No Compensation Received); Novartis – Advisory Board(Fees); Santa Ana Bio – Consultant (1099 relationship)(Fees); UCB – Other(Grants/Research Funding);
Alexandra P Charrow, MD, FAAD
Avalo – Consultant (1099 relationship)(Fees); Dermatology Foundation – Investigator(Grants/Research Funding); Hidradenitis Suppurativa Foundation – Board of Directors(No Compensation Received), Investigator(Grants/Research Funding); Incyte Corporation – Advisory Board(Fees), Investigator(No Compensation Received); Insmed – Investigator(No Compensation Received); Insmed Incorporated – Investigator(No Compensation Received); Novartis Pharmaceuticals Corp. – Advisory Board(Fees); Q32 Bio Inc. – Consultant (1099 relationship)(No Compensation Received); Sonoma Biotherapeutics – Investigator(No Compensation Received); UCB Pharma – Advisory Board(Honoraria); Wedbush Securities – Consultant (1099 relationship)(Honoraria);
Steven Daniel Daveluy, MD, FAAD
AbbVie – Advisory Board(Honoraria), Consultant (1099 relationship)(Honoraria), Speaker(Honoraria); Incyte – Advisory Board(Honoraria); Insmed – Investigator(Grants/Research Funding); MoonLake Immunotherapeutics – Investigator(Grants/Research Funding); Novartis – Speaker(Honoraria); Pfizer Inc. – Investigator(Grants/Research Funding); Regeneron – Investigator(Grants/Research Funding); Sanofi – Investigator(Grants/Research Funding); UCB – Consultant(Fees), Investigator(Grants/Research Funding), Speaker(Honoraria);
Natalie Fragoso, MD, FAAD
AbbVie – Investigator(Grants/Research Funding); Acelyrin – Investigator(Grants/Research Funding); Amgen – Investigator(Grants/Research Funding); Insmed Incorporated – Investigator(Grants/Research Funding); Takeda Pharmaceuticals USA Inc – Investigator(Grants/Research Funding); Target-Derm – Investigator(Grants/Research Funding); UCB Pharma – Consultant (1099 relationship)(Fees);
Jennifer Lin Hsiao, MD, FAAD
AbbVie – Consultant(Fees), Speaker(Fees); Aclaris Therapeutics Inc. – Consultant (1099 relationship)(Fees); Amgen – Investigator(Grants/Research Funding); Astra Zeneca – Investigator(Grants/Research Funding); Boehringer Ingelheim – Consultant(Fees), Investigator(Grants/Research Funding), Speaker(Fees); Galderma – Speaker(Fees); Incyte – Consultant (1099 relationship)(Fees), Investigator(Grants/Research Funding); Novartis – Consultant(Fees), Speaker(Fees); Pfizer Inc. – Consultant (1099 relationship)(Fees); Sanofi – Consultant (1099 relationship)(Fees); Sanofi/Regeneron – Speaker(Fees); UCB – Consultant(Fees), Speaker(Fees);
Katrina Lee, MD, FAAD
Incyte – Advisory Board(Fees), Investigator(Grants/Research Funding); Novartis Pharmaceuticals Corp. – Investigator(Grants/Research Funding);
Jonathan W Rick, MD, FAAD
Incyte Corporation – Consultant (1099 relationship)(Fees);
Christopher John Sayed, MD, FAAD
AbbVie – Advisory Board(Fees), Investigator(Fees), Speaker(Fees); Alumis – Consultant(Fees); AstraZeneca – Consultant (1099 relationship)(Fees), Investigator(Grants/Research Funding); ChemoCentryx – Investigator(Grants/Research Funding); Elasmogen – Consultant (1099 relationship)(Fees); Eli Lilly – Stockholder Public Company(Stock); Incyte – Consultant (1099 relationship)(Fees); Incyte Corporation – Investigator(Grants/Research Funding); InflaRx – Consultant(Fees), Investigator(Grants/Research Funding); MoonLake Immunotherapeutics – Consultant (1099 relationship)(Fees); Navigator Medicines – Consultant (1099 relationship)(Fees); Novartis – Investigator(Fees), Speaker(Honoraria); Sandoz Pharmaceuticals AG – Consultant (1099 relationship)(Honoraria); Sanofi – Consultant (1099 relationship)(Fees); UCB – Advisory Board(Honoraria), Consultant(Fees), Investigator(Grants/Research Funding);